Search for: "Endo Pharmaceuticals Inc"
Results 141 - 158
of 158
Sort by Relevance
|
Sort by Date
4 Oct 2009, 4:56 pm
Endo Pharmaceuticals Inc. 1:09-cv-02589; filed October 1, 2009 in the District Court of Maryland Infringement of U.S. [read post]
28 Aug 2009, 8:11 am
(patent infringement) 8/6: Ethicon Endo-Surgery Inc. v. [read post]
15 Jul 2009, 5:15 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: European Commission Competition DG releases final report on pharmaceutical sector (IPKat) (PatLit) (BLOG@IP::JUR) (IAM) (Managing Intellectual Property) (Intellectual Property Watch) (The SPC Blog) (IAM) US: Follow-on biologics proposals considered by US Senate HELP Committee; Committee passes amendment for 12-year biologics exclusivity period… [read post]
27 Feb 2009, 5:00 am
Teva Parenteral Medicines Inc. et al. [read post]
9 Jan 2009, 8:21 pm
By Jason Derry --Endo to Acquire Indevus On January 5, 2009, Endo Pharmaceuticals Holdings Inc. announced that it will buy Indevus Pharmaceuticals Inc. for an initial payment of about $370 million and an additional $267 million, based on certain milestones. [read post]
27 Oct 2008, 1:37 am
By Sherri Oslick --About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring.Endo Pharmaceuticals Inc. et al. v. [read post]
25 Oct 2008, 12:03 am
Sandoz, Inc (Law360) (Hal Wegner) (Patently-O) (Patent Prospector) (PLI) Cipro (Ciprofloxacin) - US: CAFC finds no antitrust liability for Hatch-Waxman reverse payment settlements: In Re Ciproflaxacin Hydrochloride Antitrust Litigation (IP Law Observer) Lescol (Fluvastatin) - US: Mylan confirms first-to-file patent challenge to Lescol by Novartis (SmartBrief) Levaquin (Levofloxacin) - UK: Levofloxacin SPC valid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd & Anor… [read post]
29 Aug 2008, 1:25 pm
: (IP finance), Facebook removes international access to Scrabulous, except from India: (Ars Technica), (Techdirt), Reverse engineering can resolve conflict between standardisation and competition: (Techdirt), Benefits of piracy aren’t always in the expected places: (Techdirt) Events 1-3 September: Federation of Indian Chambers of Commerce and Industry, Department of Industrial Property and Promotion, and WIPO conference on ‘Development and IP: Building synergies… [read post]
2 Aug 2008, 12:54 am
, (Daily Dose of IP), 20 August – Bill Patry Copyright Blog speaking on copyright – Melbourne: (Patry Copyright Blog), (LawFont.com), 21 August – Bill Patry Copyright Blog speaking on copyright – Canberra: (Patry Copyright Blog), (LawFont.com), 22 August – Bill Patry Copyright Blog speaking on copyright – Sydney: (Patry Copyright Blog), (LawFont.com), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat),… [read post]
21 Jul 2008, 2:37 am
Endo Pharmaceuticals Inc. et al. v. [read post]
10 Jul 2008, 5:31 pm
Nov. 6, 2000 & July 9, 2001).Texas: Ethicon Endo-Surgery, Inc. v. [read post]
8 May 2008, 12:22 pm
Wyeth Pharmaceuticals, 2008 WL 1821379 (5th Cir. [read post]
3 Apr 2008, 7:27 am
Id. at 1310-12.In Ethicon Endo-Surgery, Inc. v. [read post]
1 Feb 2008, 12:00 am
: (IPBiz),State of the Union address 28 Jan 2008: statement regarding patenting human life: (IPBiz), (Patently-O),Alnylam Pharmaceuticals secures UK patent covering molecules that affect RNA interference: (SmartBrief),Doha style compulsory licences for exports: The politics…: (Spicy IP),Pushing to compulsory licensing: Pharma companies heading closer to Doha: (Spicy IP),Financial Express on the battle between big pharma companies and the… [read post]
17 Sep 2007, 2:00 pm
See Aventis Pharma Deutschland Gmbh and King Pharmaceuticals, Inc., v. [read post]
6 Jul 2007, 4:29 am
Hoffman-La Roche, Inc., 618 N. [read post]
5 Jul 2007, 10:37 am
App. 1974).Texas: Ethicon Endo-Surgery, Inc. v. [read post]
29 Aug 2006, 11:50 am
Patent and Trademark Office about the painkiller's effectiveness thus giving Endo Pharmaceutical Holdings Inc. the right to sell a generic version. [read post]
